Addition of roxadustat to erythropoiesis‐stimulating agent (ESA) effectively corrects ESA‐hyporesponsive anaemia in patients on peritoneal dialysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13696
Abstract: Erythropoiesis‐stimulating agent (ESA) hyporesponsiveness is an important cause for the undertreatment of anaemia. A decrease in haemoglobin (Hb) levels was observed during the initial stage of the conversion from ESA to roxadustat. The study aims… read more here.
Keywords: erythropoiesis stimulating; hyporesponsive anaemia; agent esa; stimulating agent ... See more keywords